

## Radiological Case Report / Caso Clínico

## Intrapancreatic Extramedullary Plasmacytoma Mimicking Primary Pancreatic Neoplasia

### *Plasmocitoma Extramedular Intrapancreático a Mimetizar uma Neoplasia Pancreática Primária*

João Garrido Santos<sup>1</sup>, Daniela Barros<sup>2</sup>, João Lourenço<sup>3</sup>, Manuel Neves<sup>4</sup>, Celso Matos<sup>3</sup>

<sup>1</sup>Departamento de Imagiologia, Instituto Português de Oncologia do Porto, Porto, Portugal

<sup>2</sup>Departamento de Imagiologia, Hospital de Braga, Braga, Portugal

<sup>3</sup>Serviço de Radiologia, Fundação Champalimaud, Lisboa, Portugal

<sup>4</sup>Unidade de Hemato-Oncologia, Fundação Champalimaud, Lisboa, Portugal

#### Address

João Garrido Santos  
IPO-Porto  
Rua Dr. António Bernardino de Almeida  
4200-072 Porto, Portugal  
e-mail: joagarridosantos@gmail.com

Received: 22/02/2022

Accepted: 26/05/2022

Published: 30/12/2022

© Author(s) (or their employer(s)) and ARP  
2022. Re-use permitted under CC BY-NC. No commercial re-use.

#### Abstract

Extramedullary plasmacytomas are uncommon plasma cell tumors that present outside the bone marrow. The most common site where they have been found is the upper respiratory tract, while pancreatic involvement is rare. There are no specific imaging findings and usually the definite diagnosis requires biopsy. They have a good response to radiation if they are localized; when they occur as part of multiple myeloma, their outcome is dismal.

In this report, we describe a case of a pancreatic plasmacytoma in a male patient with underlying multiple myeloma in progression and history of distal pancreatectomy due to a neuroendocrine tumor, focusing on imaging findings.

#### Key-words

Pancreas; Pancreatic neoplasms; Plasmacytoma; Multiple myeloma.

#### Resumo

O Plasmocitoma extramedular é uma neoplasia rara de células plasmáticas que ocorrem fora da medula óssea. O trato respiratório superior é o local mais comum onde são encontrados, sendo o envolvimento pancreático raro. Não apresenta características imagiológicas específicas e o diagnóstico definitivo requer habitualmente biópsia.

Se ocorrer de forma localizada apresenta boa resposta à radioterapia; se ocorrer em associação a Mieloma Múltiplo têm um mau prognóstico.

Descrevemos um caso de plasmocitoma extramedular intrapancreático num doente do sexo masculino com mieloma múltiplo em progressão e antecedentes de pancreatectomia distal por tumor neuroendócrino, com enfoque nos achados imagiológicos.

#### Palavras-chave

Pâncreas; Neoplasia pancreática; Plasmocitoma; Mieloma múltiplo.

## Clinical Presentation

We present the case of a 64-year-old man with a past medical history of pancreatic neuroendocrine tumor which was being routinely followed up in our department. At the time of the first diagnosis, in 2010, he was submitted to a distal pancreatectomy and splenectomy. Later, in 2017, hepatic metastases were detected and successfully treated with chemotherapy. Besides, in 2020, he was also diagnosed with multiple myeloma (MM) and underwent a treatment with Lenalidomide, Bortezomib and Dexamethasone (VRd). However, the disease continued to progress until May 2021, when at the time a pancreatic focal lesion was detected in a routine abdominal and pelvic computed tomography (CT) and abdominal magnetic resonance imaging (MRI).


## Imaging Findings

Abdominal MRI and abdominal CT revealed a well defined focal pancreatic lesion, in the cephalic region, measuring approximately 20 mm x 27 mm, showing important restricted diffusion (Figure 1). It was hypovascular both in the arterial and the late phases, with no associated changes in the bile and pancreatic ducts (Figure 1, 2). There was no evidence of liver


metastases, although multiple vertebral lytic lesions in the context of MM were found (Figure 3). A positron emission tomography (PET) was performed revealing the lesion to be hypermetabolic (Figure 4). The endoscopic ultrasonography (EUS) showed a hypoechoic rounded mass and a sample was collected through a fine-needle biopsy. There were no adenopathies or vessel invasion. Tumor markers including CA125, CA19.9, CEA, and AFP were all within the normal limits.

The morphological pattern of the pancreatic lesion (normal main pancreatic duct) and the normal tumor markers helped to exclude a ductal adenocarcinoma. Considering the medical background of the patient, there were two possible diagnoses: recurrence of neuroendocrine tumor or intrapancreatic extramedullary plasmacytoma. The biopsy confirmed the second diagnostic hypothesis, and the tumor cells demonstrated positivity for plasma cell marker CD138 and kappa light chain, in keeping with the monoclonal nature of myeloma.


The patient completed five days of stereotactic body radiation therapy (SBRT) (median dose 30Gy) and received treatment with PACE (cisplatin, etoposide, doxorubicin and cyclophosphamide), which resulted in a partial response of the disease with complete metabolic response of pancreatic lesion on PET-CT.




**Figure 1** – MRI images of the pancreatic focal lesion, showing hyposignal on ADC map (A), hypersignal on b900 (B) and T1WI (C) and slightly hypersignal on T2WI (D). Abdominal enhanced CT (E) showing hypovascular lesion on arterial phase.



**Figure 2** – MR Cholangiopancreatography images showing the normal caliber of common bile duct and main pancreatic duct.



**Figure 3** – CT and MRI images showing multiple vertebral and iliac lytic lesions, in the context of MM.



**Figure 4**. PET-CT image showing a hypermetabolic focal pancreatic lesion in May 2021, that was not present in October 2020.

## Discussion

Extramedullary plasmacytomas are plasma cell tumours that present outside the bone marrow.<sup>1</sup> Upper respiratory tract is the most common site for extramedullary involvement (80-90%). However, all the body sites can be affected, including gastrointestinal tract (about 10%), genitourinary tract, reticuloendothelial system, thyroid, lungs, skin and testicles.<sup>2,3</sup>

Pancreatic involvement is rare, being found in approximately 2.3% of autopsies.<sup>4</sup>

Pancreatic plasmacytoma affects predominantly males and may co-occur with underlying MM, may precede the diagnosis of MM or may be a recurrence sign of MM.<sup>1</sup> The most common form of involvement is focal, but diffuse infiltration may also be seen.<sup>1,2,3,6,7</sup> The head of the pancreas is the most common site to be involved, which explains why the most common clinical findings are obstructive jaundice and abdominal pain.<sup>1,2,3,5,6,7,8</sup>

Imaging modalities for detecting the disease usually include ultrasound, CT, MRI, EUS and EUS guided fine-needle aspiration (FNA), however, imaging findings are not specific and may resemble typical findings of other pancreatic neoplasms including adenocarcinoma, neuroendocrine tumors, lymphoma and metastases.

Pancreatic adenocarcinoma originates from the ductal epithelium, causing dilatation of the main pancreatic duct. The tumor most often occurs in the pancreatic head and represents the majority of pancreatic tumors. It is usually iso or hypodense on CT scan, and it is hypointense on T1 weighted images (T1WI) and slightly hyperintense on T2 weighted images (T2WI) on MRI scan,<sup>5</sup> as in our case. Due to the hypovascularity, the tumor demonstrates only minimal enhancement compared with obvious enhancement of the normal pancreatic parenchyma. Atrophy of the distal pancreas, dilation of the main pancreatic duct and bile duct, invasion of the adjacent vessels, adenopathies, and liver metastases could also be detected in pancreatic adenocarcinoma. Our patient's tumor was hypovascular but the main pancreatic duct was not dilated, making this diagnosis less probable.

Pancreatic neuroendocrine tumors (NET) are rare tumors that originate from pluripotent stem cells in the ductal epithelium of the pancreas.<sup>5,11</sup> The tumor is iso to hypodense

on CT scan, relatively hypointense on T1WI and generally hyperintense on T2WI. Functional NETs are generally small and manifest as well-defined hypervascular lesions. Non-functioning tumors, on the other hand, are relatively larger in size, often well-defined and encapsulated, and show heterogeneous enhancement. Despite our patient's personal history of neuroendocrine tumor, the mass was hypovascular, making this diagnosis also less probable.

Primary pancreatic lymphoma is also rare and usually an extranodal manifestation of B cell non-Hodgkin's lymphoma.<sup>5</sup> Significant peripancreatic lymph node enlargement with disseminated lymphadenopathy can usually be found, but it was not the case. Pancreas is an unusual site for metastases, and they are typically seen with advanced disease.<sup>5,12</sup>

Lastly, pancreatic plasmacytoma should be considered in the differential diagnosis of a patient with multiple myeloma and a pancreatic mass, as in our case. For these reasons, biopsy

is the standard of care in cases with suspected pancreatic plasmacytoma.

There is no standardized treatment for extramedullary plasmacytoma of the pancreas. The combination of local radiation, chemotherapy, and, in selected cases, surgery is necessary for diagnosis and treatment.<sup>2</sup> In our case, the patient was treated with PACE and SBRT with complete metabolic response of pancreatic plasmacytoma on PET-CT and partial response of the disease.

Approximately 70% of patients have isolated pancreatic plasmacytoma and these cases remain disease-free for 10 years, with regional recurrence in as up to 25% of patients.<sup>13,14,15</sup> The course of the disease is more favorable in cases with primary plasmacytoma compared with those having plasmacytoma accompanying MM.<sup>5</sup>

#### Ethical disclosures / Divulgações Éticas

*Conflicts of interest:* The authors have no conflicts of interest to declare.

*Conflitos de interesse:* Os autores declaram não possuir conflitos de interesse.

*Financing Support:* This work has not received any contribution, grant or scholarship.

*Suporte financeiro:* O presente trabalho não foi suportado por nenhum subsídio ou bolsa.

*Confidentiality of data:* The authors declare that they have followed the protocols of their work center on the publication of data from patients.

*Confidencialidade dos dados:* Os autores declaram ter seguido os protocolos do seu centro de trabalho acerca da publicação dos dados de doentes.

*Protection of human and animal subjects:* The authors declare that the procedures followed were in accordance with the regulations of the relevant clinical research ethics committee and with those of the Code of Ethics of the World Medical Association (Declaration of Helsinki).

*Proteção de pessoas e animais:* Os autores declaram que os procedimentos seguidos estavam de acordo com os regulamentos estabelecidos pelos responsáveis da Comissão de Investigação Clínica e Ética e de acordo com a Declaração de Helsinquia da Associação Médica Mundial.

#### References

1. Paydas S. Pancreatic plasmacytoma: A rare but important entity for gastroenterologists, oncologists and hematologists. *J Oncol Sci.* 2019;5:109-11.
2. Pallavi R, Ravello PM, Popescu-Martinez A. An unusual pancreatic mass: a case report and literature review. *Transl Gastrointest Cancer.* 2014;3:106-10.
3. Roh YH, Hwang SY, Lee SM, Im JW, Kim JS, Kwon KA, et al. Extramedullary plasmacytoma of the pancreas diagnosed using endoscopic ultrasonography-guided fine needle aspiration. *Clin. Endosc.* 2014;47:115-18.
4. Hiller M, Goitein O, Ashkenazi YJ. Plasmacytoma of the pancreas. *IMAJ.* 2004;6:704-5.

5. Lu T, Pu H, Zhao G. Primary pancreatic plasmacytoma: a rare case report. *BMC Gastroenterol.* 2017;17:167-72.

6. Smith A, Hal H, Fraunhoffer E. Extramedullary plasmacytoma of the pancreas: a rare entity. *Case Rep Radiol.* 2012;2012:798264.

7. Hatem M, So B, Gray R, Wong J. Plasmacytoma presented as pancreatic head mass. *Radiol Case Rep.* 2015;10:81-7.

8. Hue SS, Azhar R. Plasmacytoma of the pancreas: an unusual manifestation of multiple myeloma. *Singap Med J.* 2013;54:105-7.

9. Gupta P, Rice GD, Abraham K, Ghole V, Ketkar M. Extramedullary plasmacytoma of the pancreas and jejunum. *Clin Imaging.* 2009;33:240-3.

10. Padda MS, Milles T, Adeniran AJ, Mahooti S, Aslanian HR. Pancreatic and gastric plasmacytoma presenting with obstructive jaundice, diagnosed with endoscopic ultrasound-guided fine needle aspiration. *Case Rep Gastroenterol.* 2010;4:410-5.

11. Lewis RB, Lattin GE Jr, Paal E. Pancreatic endocrine tumors: radiologic clinicopathologic correlation. *Radiographics.* 2010;30:1445-64.

12. Shah S, Mortelet K. Uncommon solid pancreatic neoplasms: ultrasound, computed tomography and magnetic resonance image features. *Semin Ultrasound CT MR.* 2007;28:357-70.

13. da Silva RL. Pancreatic involvement by plasma cell neoplasms. *J Gastrointest Cancer.* 2012;43:157-67.

14. McKenna RW, Kyle RA, Kuehl WM, Grogan TM, Harris NL, Coupland RW. Plasma cell neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al., eds. *WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues.* fourth ed. Lyon, France: International Agency for Research on Cancer; 2008:200-208.

15. Pan Q, Luo Y, Li J, Zhang S, Li F. Recurrence of extramedullary plasmacytomas involving lymph nodes and pancreas revealed by 68Ga-DOTATATE and 18F-FDG PET/CT. *Clin Nucl Med.* 2018;43:936-8.